SGT-212
Phase 1Recruiting 0 watching 0 views this week๐ค Quiet
25
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich's Ataxia (FA)
Conditions
Friedreich's Ataxia (FA)
Trial Timeline
Oct 22, 2025 โ Feb 29, 2032
NCT ID
NCT07180355About SGT-212
SGT-212 is a phase 1 stage product being developed by Solid Biosciences for Friedreich's Ataxia (FA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07180355. Target conditions include Friedreich's Ataxia (FA).
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07180355 | Phase 1 | Recruiting |
Competing Products
11 competing products in Friedreich's Ataxia (FA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Interferon ฮณ-1b | Amgen | Phase 3 | 76 |
| interferon ฮณ-1b | Amgen | Phase 3 | 76 |
| Interferon ฮณ-1b + Placebo | Amgen | Phase 3 | 76 |
| varenicline + placebo | Pfizer | Phase 2/3 | 64 |
| Lu AA24493 + Placebo | Lundbeck | Phase 2 | 49 |
| Omeveloxolone | Biogen | Pre-clinical | 20 |
| Placebo + EPI-743 400 mg + EPI-743 200 mg | PTC Therapeutics | Phase 2 | 49 |
| idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |
| Idebenone + Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |
| Idebenone | Santhera Pharmaceuticals | Phase 3 | 69 |
| Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |